Advanced search

Vol 15, No 2 (2011)
Review paper
Published online: 2011-05-26

open access

View PDF (Polish) Download PDF file
Page views 1281
Article views/downloads 7189
Get Citation

Connect on Social Media

Connect on Social Media

Influence of genetic factors on early hypertensive complications

Katarzyna Polonis, Michał Hoffmann, Krzysztof Narkiewicz
Nadciśnienie tętnicze 2011;15(2):125-142.

Abstract

Hypertension is the most prevalent risk factor for cardiovascular disease (CVD), the leading cause of death worldwide, especially in developed countries. Genetic and environmental determinants play important roles in hypertension and its complications. This publication gives a short introduction to the pathogenesis of CVD and summarizes the current findings of the genetic factors involved. This review focuses on a better understanding of the role of candidate genes polymorphisms that play a crucial role in blood pressure regulation, hemostatic processes, oxidative stress and inflammatory responses leading to endothelial damage, and as a result, to vascular remodeling and microalbuminuria. Those gene variants could contribute to inter-individual differences in susceptibility to and outcome of essential hypertension. Therefore, the major challenge in cardiovascular medicine is to find a way of predicting the risk of hypertension complications by genetic markers that, used with imaging techniques, could lead to the development of new and better diagnostic and therapeutic methods.
Arterial Hypertension 2011, vol. 15, no 2, pages 125–142.

Keywords: hypertensiongene polymorphismgenetic markersendothelium damagevascular remodelingalbuminuria

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000; 13(1 Pt 2): 3S–310S.
    PubMed
  2. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000; 14(2): 83–90.
    PubMed
  3. Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res. 2009; 58(supl. 2): S33–S41.
  4. Kuznetsova T, Staessen JA, Brand E, et al. European Project on Genes in Hypertension Investigators. Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. J Hypertens. 2006; 24(2): 235–242.
    CrossRefPubMed
  5. Pasierski T, Grodzicki T. Podłoże genetyczne powikłań nadciśnienia tętniczego w układzie sercowo-naczyniowym. In: Ciechanowicz A, Januszewicz A, Januszewicz W, Ruyłło W. ed. Genetyka chorób układu krążenia. Medycyna Praktyczna, Kraków 2002: 207–210.
  6. Ciechanowicz A. Molekularne podłoże nadciśnienia tętniczego-przegląd genów kandydatów. Genetyka chorób układu krążenia. In: Ciechanowicz A, Januszewicz A, Januszewicz W, Rużyłło W. ed. Genetyka chorób układu krążenia. Medycyna Praktyczna, Kraków 2002: 191–198.
  7. Gryglewska B, Nęcki M, Grodzicki T. Mikrokrążenie a nadciśnienie tętnicze. Nadciśnienie Tętnicze. 2001; 5(4): 229–234.
  8. Lewartowski B. Budowa i funkcja naczyń w nadciśnieniu tętniczym. In: Januszewicz A, Januszewicz W, Szczepańska-Sadowska E, Sznajderman M. ed. Nadciśnienie tętnicze. Medycyna Praktyczna, Kraków 2007: 159–170.
  9. Wnuczko K, Szczepański M. Śródbłonek — charakterystyka i funkcje. Pol Merk Lek. 2007; 23(133): 60–65.
  10. Sung KiC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003; 16(6): 429–433.
    PubMed
  11. Boos CJ, Lip GYH. Is hypertension an inflammatory process? Curr Pharm Des. 2006; 12(13): 1623–1635.
    PubMed
  12. Kuklinska AM, Mroczko B, Musial WJ, et al. High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia. Adv Med Sci. 2009; 54(2): 225–232.
    CrossRefPubMed
  13. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003; 21(3): 315–325.
    PubMed
  14. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004; 62(4): 499–506.
    CrossRefPubMed
  15. Zhu XY, Daghini E, Chade AR, et al. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol. 2006; 26(8): 1746–1752.
    CrossRefPubMed
  16. Félétou M, Köhler R, Vanhoutte PM. Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep. 2010; 12(4): 267–275.
    CrossRefPubMed
  17. Luscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens. 1994; 12(10): S105–S116.
  18. Martynowicz H, Skoczyńska A, Silber M, et al. Rola stresu oksydacyjnego w patogenezie nadciśnienia tętniczego. Nadciśnienie Tętnicze. 2004; 8(6): 431–438.
  19. Xu S, Touyz RM. Reactive oxygen species and vascular remodelling in hypertension: still alive. Can J Cardiol. 2006; 22(11): 947–951.
    PubMed
  20. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004; 122(4): 339–352.
    CrossRefPubMed
  21. Touyz R. Oxidative stress and vascular damage in hypertension. Current Hypertension Reports. 2000; 2(1): 98–105.
    CrossRef
  22. Chłopicki S. Śródbłonek w patogenezie i farmakoterapii powikłań miażdżycowych nadciśnienia tętniczego. In: Januszewicz A, Januszewicz W, Szczepańska-Sadowska E, Sznajderman M. ed. Nadciśnienie tętnicze. Medycyna Praktyczna, Kraków 2007: 263–274.
  23. Filipiak KJ, Opolski G. Genetyczne uwarunkowania czynności śródbłonka. Genetyka chorób układu krążenia. In: Ciechanowicz A, Januszewicz A, Januszewicz W, Rużyłło W. ed. Genetyka chorób układu krążenia. Medycyna Praktyczna, Kraków 2002: 55–62.
  24. Lechi C, Gaino S, Zuliani V, et al. Elevated plasma fibrinogen levels in patients with essential hypertension are related to vascular complications. Int Angiol. 2003; 22(1): 72–78.
    PubMed
  25. Diamantopoulos E, Andreadis E, Vassilopoulos C, et al. Increased Plasma Plasminogen Activator Inhibitor‐1 Levels: A Possible Marker of Hypertensive Target Organ Damage. Clinical and Experimental Hypertension. 2003; 25(1): 1–9.
    CrossRef
  26. Bujak R, Sinkiewicz W, Błażejewski J, et al. Tkankowy aktywator plazminogenu (t - PA) i jego inhibitor typu 1 (PAI - 1) u chorych z ostrym zawałem serca. Folia Cardiol. 2002; 4: 311–318.
  27. Grubic N, Stegnar M, Peternel P, et al. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res. 1996; 84(6): 431–443.
    PubMed
  28. Kucukarabaci B, Gunes HV, Ozdemir G, et al. Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke. Genet Test. 2008; 12(3): 443–451.
    CrossRefPubMed
  29. Mlynarska A, Waszyrowski T, Kasprzak JD. Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J Thromb Haemost. 2006; 4(6): 1361–1366.
    CrossRefPubMed
  30. Anvari A, Schuster E, Gottsauner-Wolf M, et al. PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res. 2001; 103(2): 103–107.
    PubMed
  31. Jastrzębska M, Widecka K, Ciechanowicz A, et al. imorfizmy 4G/5G genu inhibitora aktywatora plazminogenu (PAI - 1) oraz I/D genu enzymu konwertującego angiotensynę I (ACE) a aktywność fibrynolityczna u chorych z samoistnym nadciśnieniem tętniczym i dyslipidemią. Pol Arch Med Wewn. 2005; 113(1): 7–20.
  32. Asselbergs FW, Williams SM, Hebert PR, et al. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics. 2007; 89(3): 362–369.
    CrossRefPubMed
  33. Zhao R, Ma X, Shen GX. Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem. 2008; 317(1-2): 197–204.
    CrossRefPubMed
  34. Makris TK, Stavroulakis GA, Dafni UG, et al. ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension. Am Heart J. 2000; 140(5): 760–765.
    CrossRefPubMed
  35. VISCHER UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. Journal of Thrombosis and Haemostasis. 2006; 4(6): 1186–1193.
    CrossRef
  36. van Schie MC, van Loon JE, de Maat MPM, et al. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011; 9(5): 899–908.
    CrossRefPubMed
  37. Nakamura S, Nakamura I, Ma L, et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000; 58(1): 251–259.
    CrossRefPubMed
  38. Sekuri C, Cam FS, Ercan E, et al. Renin-angiotensin system gene polymorphisms and premature coronary heart disease. J Renin Angiotensin Aldosterone Syst. 2005; 6(1): 38–42.
    CrossRefPubMed
  39. Steeds RP, Wardle A, Smith PD, et al. Analysis of the postulated interaction between the angiotensin II sub-type 1 receptor gene A1166C polymorphism and the insertion/deletion polymorphism of the angiotensin converting enzyme gene on risk of myocardial infarction. Atherosclerosis. 2001; 154(1): 123–128.
    PubMed
  40. Mansego ML, Solar GD, Alonso MP, et al. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens. 2011; 29(3): 492–500.
    CrossRefPubMed
  41. Heltianu C, Costache G, Gafencu A, et al. Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction. J Cell Mol Med. 2005; 9(1): 135–142.
    PubMed
  42. Zintzaras E, Kitsios G, Stefanidis I. Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension. 2006; 48(4): 700–710.
    CrossRefPubMed
  43. Fairchild TA, Fulton D, Fontana JT, et al. Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)-->Asp variant of human endothelial nitric-oxide synthase. J Biol Chem. 2001; 276(28): 26674–26679.
    CrossRefPubMed
  44. Salimi S, Firoozrai M, Zand H, et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism in patients with coronary artery disease. Ann Saudi Med. 2010; 30(1): 33–37.
    CrossRefPubMed
  45. Nakayama M, Yasue H, Yoshimura M, et al. T-786->C Mutation in the 5'-Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm. Circulation. 1999; 99(22): 2864–2870.
    CrossRef
  46. Jemaa R, Kallel A, Sediri Y, et al. Association between -786TC polymorphism in the endothelial nitric oxide synthase gene and hypertension in the Tunisian population. Exp Mol Pathol. 2011; 90(2): 210–214.
    CrossRefPubMed
  47. Negrao MV, Alves CR, Alves GB, et al. Exercise training improves muscle vasodilatation in individuals with T786C polymorphism of endothelial nitric oxide synthase gene. Physiol Genomics. 2010; 42A(1): 71–77.
    CrossRefPubMed
  48. Fatini C, Sofi F, Gensini F, et al. Influence of eNOS gene polymorphisms on carotid atherosclerosis. Eur J Vasc Endovasc Surg. 2004; 27(5): 540–544.
    CrossRefPubMed
  49. Tsukada T, Yokoyama K, Arai T, et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun. 1998; 245(1): 190–193.
    CrossRefPubMed
  50. Mehrab-Mohseni M, Tabatabaei-Malazy O, Hasani-Ranjbar S, et al. Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications. Diabetes Res Clin Pract. 2011; 91(3): 348–352.
    CrossRefPubMed
  51. Banecka - Ma, Gąsecki D, Jakóbkiewicz - Ba, et al. Hiperhomocysteinemia — ważny czynnik ryzyka udaru mózgu. Udar Mózgu. 2005; 7(2): 61–65.
  52. Kraczkowska S, Suchocka Z, Pachecka J. Podwyższone stężenie homocysteiny we krwi jako wskaźnik zagrożenia zdrowia. Biul Wydz Farm WUM. 2005; 3: 19–24.
  53. Palko-Labuz A, Sadkierska-Chudy A, Pilecki W. The genetic background of thrombosis — the distribution of factor V leiden, prothrombin G20210A and MTHFR C677T polymorphism. Adv Clin Exp Med. 2010; 19(1): 51–55.
  54. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21): 2588–2605.
    CrossRefPubMed
  55. Kass DA. Age-related changes in venticular-arterial coupling: pathophysiologic implications. Heart Fail Rev. 2002; 7(1): 51–62.
    PubMed
  56. Tomiyama H, Arai T, Koji Y, et al. The age-related increase in arterial stiffness is augmented in phases according to the severity of hypertension. Hypertens Res. 2004; 27(7): 465–470.
    PubMed
  57. Pędzich E, Szmigielski C, Gaciong Z. Ciśnienie centralne jako wskaźnik ryzyka powikłań sercowo - naczyniowych. Naciśnienie Tętnicze. 2006; 10(5): 341–349.
  58. Jankowski P, Kawecka-Jaszcz K. Central blood pressure and cardiovascular risk. J Hypertens. 2009; 27(8): 1713.
    CrossRefPubMed
  59. Rajzer M. Kawecka - Jaszcz K. Podatność tętnic w nadciśnieniu tętniczym. Od patofizjologii do znaczenia klinicznego. Nadciśnienie Tętnicze. 2002; 6(1): 61–73.
  60. Cwynar M, Wojciechowska W. Kawecka - Jaszcz K., Grodzicki T. Mechanizmy przebudowy dużych naczyń tętniczych. Przegląd Lekarski. 2002; 59(supl. 3): 1–8.
  61. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005; 45(6): 1050–1055.
    CrossRefPubMed
  62. Kubalski P, Manitius J. Sztywność tętnic, ciśnienie centralne, współczynnik wzmocnienia — kompendium nie tylko dla hipertensjologa. Choroby Serca i Naczyń. 2008; 5(2): 61–67.
  63. Laurent S. Nadciśnienie tętnicze i choroba dużych naczyń. Choroby Serca i Naczyń. 2007; 4(3): 113–116.
  64. Trzebski A. Odruchowa regulacja krążenia krwi w nadciśnieniu tętniczym. In: Januszewicz A, Januszewicz W, Szczepańska-Sadowska E, Sznajderman M. ed. Nadciśnienie tętnicze. Medycyna Praktyczna, Kraków 2007: 171–198.
  65. Vastagh I, Horváth T, Nagy G, et al. Evolution and predictors of morphological and functional arterial changes in the course of type 1 diabetes mellitus. Diabetes Metab Res Rev. 2010; 26(8): 646–655.
    CrossRefPubMed
  66. Scallan C, Doonan RJ, Daskalopoulou SS. The combined effect of hypertension and smoking on arterial stiffness. Clin Exp Hypertens. 2010; 32(6): 319–328.
    CrossRefPubMed
  67. Doonan RJ, Hausvater A, Scallan C, et al. The effect of smoking on arterial stiffness. Hypertens Res. 2010; 33(5): 398–410.
    CrossRefPubMed
  68. Wilkinson I, Cockcroft JR. Cholesterol, lipids and arterial stiffness. Adv Cardiol. 2007; 44: 261–277.
    CrossRefPubMed
  69. Kingwell B, Boutouyrie P. Genetic influences on the arterial wall. Clin Exp Pharmacol Physiol. 2007; 34(7): 652–657.
    CrossRefPubMed
  70. Szczepańska-Sadowska E, Cudnoch-Jędrzejewska A. Układ renina-angiotensyna-aldosteron — główny układ hormonalny w rozwoju nadciśnienia tętniczego. In: Szczepańska-Sadowska E, Januszewicz A, Januszewicz W, Sznajderman M. ed. Nadciśnienie Tętnicze. Medycyna Praktyczna, Kraków 2007: 199–222.
  71. Bozec E, Lacolley P, Bergaya S, et al. Arterial stiffness and angiotensinogen gene in hypertensive patients and mutant mice. J Hypertens. 2004; 22(7): 1299–1307.
    PubMed
  72. Baker M, Rahman T, Hall D, et al. The C-532T polymorphism of the angiotensinogen gene is associated with pulse pressure: a possible explanation for heterogeneity in genetic association studies of AGT and hypertension. Int J Epidemiol. 2007; 36(6): 1356–1362.
    CrossRefPubMed
  73. Benetos A, Gautier S, Ricard S, et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation. 1996; 94(4): 698–703.
    PubMed
  74. Rehman A, Rasool AH. G., Naing L., Roshan T.M., Rahman A.R.A. Influence of the angiotensin II type I receptor gene 1166A>C polymorhism on BP and aortic pulse wave velocity among Malays. Ann Hum Genet. 2007; 71(1): 860–895.
  75. Lajemi M, Labat C, Gautier S, et al. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens. 2001; 19(3): 407–413.
    PubMed
  76. Nürnberger J, Opazo Saez A, Mitchell A, et al. The T-allele of the C825T polymorphism is associated with higher arterial stiffness in young healthy males. J Hum Hypertens. 2004; 18(4): 267–271.
    CrossRefPubMed
  77. Olszanecka A, et al. Kawecka - Jaszcz K., Stolarz K. Polimorfizm podjednostki b3 białka G a ciśnienie tętnicze i struktura i funkcja naczyń krwionośnych. Nadciśnienie Tętnicze. 2004; 8(2): 119–131.
  78. Benetos A, Gautier S, Ricard S, et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation. 1996; 94(4): 698–703.
    PubMed
  79. Dima I, Vlachopoulos C, Alexopoulos N, et al. Association of arterial stiffness with the angiotensin-converting enzyme gene polymorphism in healthy individuals. Am J Hypertens. 2008; 21(12): 1354–1358.
    CrossRefPubMed
  80. Cwynar M, Wojciechowska W, Stolarz K. Wpływ interakcji polimorfizmów G - 6A genu AGT, D/I genu ACE oraz A1166C genu AGTR1 na ciśnienie tętnicze oraz na parametry usztywnienia tętnic. Nadciśnienie Tętnicze. 2007; 11(2): 95–105.
  81. Taniwaki H, Kawagishi T, Emoto M, et al. Association of ACE gene polymorphism with arterial stiffness in patients with type 2 diabetes. Diabetes Care. 1999; 22(11): 1858–1864.
    PubMed
  82. Mattace-Raso FUS, van der Cammen TJM, Sayed-Tabatabaei FA, et al. Angiotensin-converting enzyme gene polymorphism and common carotid stiffness. The Rotterdam study. Atherosclerosis. 2004; 174(1): 121–126.
    CrossRefPubMed
  83. Sie MPS, Yazdanpanah M, Mattace-Raso FUS, et al. Genetic variation in the renin-angiotensin system and arterial stiffness. The Rotterdam Study. Clin Exp Hypertens. 2009; 31(5): 389–399.
    PubMed
  84. Zhang H, Thijs L, Kuznetsova T, et al. Progression to hypertension in the non-hypertensive participants in the Flemish Study on Environment, Genes and Health Outcomes. J Hypertens. 2006; 24(9): 1719–1727.
    CrossRefPubMed
  85. Seidlerová J. Adducin and its relation to cardiovascular system. Artery Research. 2010; 4(4): 134–137.
    CrossRef
  86. Balkestein EJ, Wang JiG, Struijker-Boudier HAJ, et al. Carotid and femoral intima-media thickness in relation to three candidate genes in a Caucasian population. J Hypertens. 2002; 20(8): 1551–1561.
    PubMed
  87. Pojoga L, Gautier S, Blanc H, et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens. 1998; 11(7): 856–860.
    PubMed
  88. Wojciechowska W, Staessen JA, Stolarz K, et al. European Project on Genes in Hypertension (EPOGH) Investigators. Association of peripheral and central arterial wave reflections with the CYP11B2 -344C allele and sodium excretion. J Hypertens. 2004; 22(12): 2311–2319.
    PubMed
  89. Safar ME, Cattan V, Lacolley P, et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens. 2005; 23(6): 1159–1166.
    PubMed
  90. Blacher J, Kakou A, Lacombe JM, et al. Preferential association of aldosterone synthase gene polymorphism with central blood pressure and wave reflections in hypertensive individuals. J Hum Hypertens. 2010; 24(4): 291–299.
    CrossRefPubMed
  91. Wojciechowska W, Cwynar M, et al. Stolarz - Skrzypek K. Związek polimorfizmu genów syntazy aldosteronu i a adducyny ze zmiennością ciśnienia tętniczego (SBPM). Nadciśnienie Tętnicze. 2007; 11(2): 53–59.
  92. Lipka D, Boratyński J. Metaloproteinazy MMP. Struktura i ich funkcja. Postępy Hig Med Dośw. 2008; 62: 328–336.
  93. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17: 4663–4516.
  94. Santos-Martínez MJ, Medina C, Jurasz P, et al. Role of metalloproteinases in platelet function. Thromb Res. 2008; 121(4): 535–542.
    CrossRefPubMed
  95. Mulvany MJ, Baumbach GL, Aalkjaer C. Vascular remodeling. Hypertension. 1996; 28: 505–506.
  96. De Mey JoGR, Schiffers PM, Hilgers RHP, et al. Toward functional genomics of flow-induced outward remodeling of resistance arteries. Am J Physiol Heart Circ Physiol. 2005; 288(3): H1022–H1027.
    CrossRefPubMed
  97. Lee HY, Oh BH. Aging and arterial stiffness. Circ J. 2010; 74(11): 2257–2262.
    PubMed
  98. Briones AM, Arribas SM, Salaices M. Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens. 2010; 19(2): 187–194.
    CrossRefPubMed
  99. Powell JT, Turner RJ, Sian M, et al. Influence of fibrillin-1 genotype on the aortic stiffness in men. J Appl Physiol (1985). 2005; 99(3): 1036–1040.
    CrossRefPubMed
  100. Medley TL, Cole TJ, Gatzka CD, et al. Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease. Circulation. 2002; 105(7): 810–815.
    PubMed
  101. Yasmin, O’Shaughnessy K.M., McEniery C.M., Cockcroft .R., Wilkinson I.B. Genetic variation in fibrilin - 1 gene is not associated with arterial stiffness in apparently healthy inviduals. J Hypertens. 2006; 24: 499–502.
  102. Zhu C, Odeberg J, Hamsten A, et al. Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun. 2006; 348(3): 1150–1156.
    CrossRefPubMed
  103. Bini A, Itoh Y, Kudryk BJ, et al. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Biochemistry. 1996; 35(40): 13056–13063.
    CrossRefPubMed
  104. Medley TL, Kingwell BA, Gatzka CD, et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res. 2003; 92(11): 1254–1261.
    CrossRefPubMed
  105. Beilby JP, Chapman CML, Palmer LJ, et al. Stromelysin-1 (MMP-3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population. J Hypertens. 2005; 23(3): 537–542.
    PubMed
  106. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002; 91(9): 852–859.
    PubMed
  107. McEniery CM, Wallace S, Dakham Z, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25(2): 372–373.
    CrossRefPubMed
  108. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999; 99(14): 1788–1794.
    PubMed
  109. Medley TL, Cole TJ, Dart AM, et al. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol. 2004; 24(8): 1479–1484.
    CrossRefPubMed
  110. Blankenberg S, Rupprecht HJ, Poirier O, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107(12): 1579–1585.
    CrossRefPubMed
  111. McEniery CM, O'Shaughnessy KM, Harnett P, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol. 2006; 26(8): 1799–1805.
    CrossRefPubMed
  112. 2007 guidelines for the management of arterial hypertension. Eur. Heart J. 2007; 28: 1462–1536.
  113. Paternoster L, Martinez-Gonzales NA, Charleton R, et al. Geneticic effects on carotid intima - media thickness (Systematic assessment and meta - analyses of candidate gene polymorphism studies in more than 5000 subjects). Circ Cardiovasc Genet. 2010; 3(1): 15–21.
  114. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res. 2008; 52(1): 131–145.
    CrossRefPubMed
  115. Nyholt DR, Yu CE, Visscher PM. On Jim Watson's APOE status: genetic information is hard to hide. Eur J Hum Genet. 2009; 17(2): 147–149.
    CrossRefPubMed
  116. Manolio TA, Boerwinkle E, O'Donnell CJ, et al. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24(9): 1567–1577.
    CrossRefPubMed
  117. Alioglu E, Turk U, Cam S, et al. Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness. Can J Cardiol. 2009; 25(1): e1–e5.
    PubMed
  118. Liao YC, Lin HF, Rundek T, et al. Segment-specific genetic effects on carotid intima-media thickness: the Northern Manhattan study. Stroke. 2008; 39(12): 3159–3165.
    CrossRefPubMed
  119. Bonithon-Kopp C, Ducimetière P, Touboul PJ, et al. Plasma angiotensin-converting enzyme activity and carotid wall thickening. Circulation. 1994; 89(3): 952–954.
    PubMed
  120. Castellano M, Muiesan ML, Rizzoni D, et al. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. Circulation. 1995; 91(11): 2721–2724.
    PubMed
  121. Rundek T, Elkind MS, Pittman J, et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke. 2002; 33(5): 1420–1423.
    PubMed
  122. Armstrong C, Abilleira S, Sitzer M, et al. Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke. 2007; 38(11): 2895–2899.
    CrossRefPubMed
  123. Ghilardi G, Biondi ML, DeMonti M, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke. 2002; 33(10): 2408–2412.
    PubMed
  124. Futrakul N, Sridama V, Futrakul P. Microalbuminuria--a biomarker of renal microvascular disease. Ren Fail. 2009; 31(2): 140–143.
    CrossRefPubMed
  125. Lewandowicz A. Mikroalbuminuria — wciąż fascynujące zagadnienie. Kardiologia na co Dzień. 2009; 4(1): 3–8.
  126. Wachtell K. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. Annals of Internal Medicine. 2003; 139(11): 901–906.
    CrossRef
  127. Redon J, Martinez F, Pascual JM. Mikroalbuminuria w samoistnym nadciśnieniu tętniczym. Choroby Serca i Naczyń. 2008; 5(3): 121–124.
  128. Redon J, Pascual JM. Development of microalbuminuria in essential hypertension. Curr Hypertens Rep. 2006; 8(2): 171–177.
    PubMed
  129. Martinez F, Mansego ML, Chaves FJ, et al. Genetic bases of urinary albumin excretion and related traits in hypertension. J Hypertens. 2010; 28(2): 213–225.
    PubMed
  130. Rovira E, Chaves FJ, Julve R, et al. [Insertion/deletion polymorphism of the gene encoding for angiotensin-converting enzyme and microalbuminuria in essential arterial hypertension]. Med Clin (Barc). 1999; 112(19): 726–730.
    PubMed
  131. Redon J, Chaves FJ, Liao Y, et al. Influence of the I/D polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension. Hypertension. 2000; 35(1 Pt 2): 490–495.
    PubMed
  132. Pedrinelli R, Dell'Omo G, Penno G, et al. Alpha-adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. J Hypertens. 2006; 24(5): 931–937.
    CrossRefPubMed
  133. Chaves FJ, Pascual JM, Rovira E, et al. Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. Am J Hypertens. 2001; 14(4 Pt 1): 364–370.
    PubMed
  134. Buraczynska M. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrology Dialysis Transplantation. 2005; 21(4): 979–983.
    CrossRef
  135. Ishigami T, Umemura S, Tamura K, et al. Essential hypertension and 5' upstream core promoter region of human angiotensinogen gene. Hypertension. 1997; 30(6): 1325–1330.
    PubMed
  136. Marin P, Julve R, Chaves FJ, et al. Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study. J Hum Hypertens. 2004; 18(1): 25–31.
    CrossRefPubMed
  137. Pereira AC, Floriano MS, Mota GFA, et al. Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension. 2003; 42(4): 685–692.
    CrossRefPubMed
  138. Masuo K, Katsuya T, Sugimoto K, et al. High plasma norepinephrine levels associated with beta2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals. Hypertens Res. 2007; 30(6): 503–511.
    CrossRefPubMed
  139. Kobayashi Y, Nakayama T, Sato N, et al. Haplotype-based case-control study revealing an association between the adrenomedullin gene and proteinuria in subjects with essential hypertension. Hypertens Res. 2005; 28(3): 229–236.
    CrossRefPubMed
  140. Baltyn J, Soldacki D, Zygier M, et al. Adrenomedulina — spojrzenie z perspektywy 10 lat od jej odkrycia. Kardiologia po Dyplomie. 2003; 2(5): 111.
  141. Ishimitsu T, Ono H, Minami J, et al. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther. 2006; 111(3): 909–927.
    CrossRefPubMed
  142. Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science. 2003; 300(5617): 286–290.
    CrossRefPubMed
  143. Luco RF, Allo M, Schor IE, et al. Epigenetics in alternative pre-mRNA splicing. Cell. 2011; 144(1): 16–26.
    CrossRefPubMed
  144. Hui J. Regulation of mammalian pre-mRNA splicing. Sci China C Life Sci. 2009; 52(3): 253–260.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note